scholarly journals Mistaken administration of a repeat loading dose of Degarelix leading to acute psychosis

JRSM Open ◽  
2021 ◽  
Vol 12 (2) ◽  
pp. 205427042098310 ◽  
Author(s):  
Musaab Hamdoon ◽  
Maria Satchi ◽  
Fay Fawke ◽  
Sanjeev Madaan
Keyword(s):  
Prostate Cancer ◽  
Side Effects ◽  
Luteinising Hormone ◽  
Metastatic Prostate Cancer ◽  
Panic Attacks ◽  
Loading Dose ◽  
Acute Psychosis ◽  
Visual Hallucinations ◽  
Releasing Hormone ◽  
Hormone Antagonists

Lesson Advanced and metastatic prostate cancer is often managed with hormonal blockage. Luteinising hormone-releasing hormone antagonists achieve rapid testosterone suppression and are used for the treatment of advanced or metastatic prostate cancer. Degarelix is a luteinising hormone-releasing hormone antagonist and is given as a loading dose, followed by a monthly maintenance dose. We report a case where a patient was inadvertently given a second loading dose of Degarelix that resulted in acute psychosis in the form of panic attacks, delusions, suicidal thoughts, insomnia and some visual hallucinations, which are not reported as side-effects of Degarelix.

Bicalutamide-associated hallucinations in a metastatic prostate cancer patient: A case report

2019 ◽  
Vol 26 (4) ◽  
pp. 1029-1031 ◽  
Author(s):  
Gorkem Turkkan ◽  
Caner Dogan ◽  
Burak Tek
Keyword(s):  
Prostate Cancer ◽  
Case Report ◽  
Side Effects ◽  
Luteinizing Hormone ◽  
Metastatic Prostate Cancer ◽  
Plasma Testosterone ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Uncommon Case ◽  
To Receive

Introduction Bicalutamide is widely used in the treatment of prostate cancer. Among its side effects, central nervous system disorders are relatively rare, and the information about bicalutamide-associated hallucinations is limited. Case report We report an uncommon case of a patient with metastatic prostate cancer, who had hallucinations due to the use of bicalutamide. Management and outcome The patient accepted to receive only hormonal therapy (bicalutamide and leuprolide acetate). But he developed hallucinations due to bicalutamide use. His hallucinations disappeared after discontinuation of bicalutamide. A good response was obtained with the use of luteinizing hormone-releasing hormone agonist monotherapy. Discussion The pathophysiology of bicalutamide-induced hallucinations is unclear. We hypothesize that antiandrogens can indirectly cause hallucinations through changes in plasma testosterone and cerebral reelin expression. Additionally, luteinizing hormone-releasing hormone agonist monotherapy is a good option in metastatic prostate cancer patients who have intolerable side effects due to the use of antiandrogens.

Luteinising hormone-releasing hormone antagonists in prostate cancer therapy

2007 ◽  
Vol 12 (2) ◽  
pp. 285-299 ◽  
Author(s):  
Pavlos Msaouel ◽  
Evanthia Diamanti ◽  
Marinela Tzanela ◽  
Michael Koutsilieris
Keyword(s):  
Prostate Cancer ◽  
Cancer Therapy ◽  
Luteinising Hormone ◽  
Releasing Hormone ◽  
Prostate Cancer Therapy ◽  
Hormone Antagonists

Bilateral Orchiectomy With or Without Flutamide for Metastatic Prostate Cancer

2021 ◽  
pp. 73-76
Author(s):  
Philipp Dahm
Keyword(s):  
Prostate Cancer ◽  
Side Effects ◽  
Randomized Trial ◽  
Survival Benefit ◽  
Metastatic Prostate Cancer ◽  
Androgen Deprivation ◽  
Bilateral Orchiectomy

This chapter summarizes the findings of a landmark randomized trial comparing total androgen deprivation in the form of bilateral orchiectomy plus the antiandrogen flutamide to bilateral orchiectomy alone. The study found no survival benefit but did find increased side effects from the addition of an antiandrogen.

Sign in / Sign up

Export Citation Format

Share Document